Reference - Detail
| RRC ID | 65457 |
|---|---|
| Author | Goto S, Sakoda Y, Adachi K, Sekido Y, Yano S, Eto M, Tamada K. |
| Title | Enhanced anti-tumor efficacy of IL-7/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models. |
| Journal | Cancer Immunol Immunother |
| Abstract |
Chimeric antigen receptor (CAR)-T cell therapy has impressive efficacy in hematological malignancies, but its application in solid tumors remains a challenge. Multiple hurdles associated with the biological and immunological features of solid tumors currently limit the application of CAR-T cells in the treatment of solid tumors. Using syngeneic mouse models, we recently reported that CAR-T cells engineered to concomitantly produce interleukin (IL)-7 and chemokine (C-C motif) ligand 19 (CCL19)-induced potent anti-tumor efficacy against solid tumors through an improved ability of migration and proliferation even in an immunosuppressive tumor microenvironment. In this study, for a preclinical evaluation preceding clinical application, we further explored the potential of IL-7/CCL19-producing human CAR-T cells using models that mimic the clinical features of solid tumors. Human anti-mesothelin CAR-T cells producing human IL-7/CCL19 achieved complete eradication of orthotopic pre-established malignant mesothelioma and prevented a relapse of tumors with downregulated antigen expression. Moreover, mice with patient-derived xenograft of mesothelin-positive pancreatic cancers exhibited significant inhibition of tumor growth and prolonged survival following treatment with IL-7/CCL19-producing CAR-T cells, compared to treatment with conventional CAR-T cells. Transfer of IL-7/CCL19-producing CAR-T cells resulted in an increase in not only CAR-T cells but also non-CAR-T cells within the tumor tissues and downregulated the expression of exhaustion markers, including PD-1 and TIGIT, on the T cells. Taken together, our current study elucidated the exceptional anti-tumor efficacy of IL-7/CCL19-producing human CAR-T cells and their potential for clinical application in the treatment of patients with solid tumors. |
| Volume | 70(9) |
| Pages | 2503-2515 |
| Published | 2021-9-1 |
| DOI | 10.1007/s00262-021-02853-3 |
| PII | 10.1007/s00262-021-02853-3 |
| PMID | 33559069 |
| MeSH | Animals Cell Line, Tumor Chemokine CCL19 / genetics Chemokine CCL19 / metabolism* Disease Models, Animal Female Humans Immunophenotyping Immunotherapy, Adoptive* / methods Interleukin-7 / genetics Interleukin-7 / metabolism* Mesothelin Mesothelioma, Malignant / etiology Mesothelioma, Malignant / pathology Mesothelioma, Malignant / therapy Mice Mice, Knockout Receptors, Chimeric Antigen Recurrence T-Lymphocytes / immunology* T-Lymphocytes / metabolism* T-Lymphocytes / pathology Treatment Outcome Xenograft Model Antitumor Assays |
| IF | 5.442 |
| Altmetric score |
オルトメトリクス指標項目
|
| The most frequently cited source | X(Twitter) |
| Total number of mentions | 7 |
| Altmetric score changes over past 6months | 0.0 |
| Resource | |
| Human and Animal Cells | OV2944-HM-1(RCB1483) |